AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34887528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 24IU oxytocin
Number of subjects: 220
Study 34887528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 34461991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise + vitamin D Supplementation (AE + VitD)
Number of subjects: 40
Study 34461991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 40
Study 34461991 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation (VitD)
Number of subjects: 40
Study 34461991 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40
Study 36341537 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency item response options on depression and generalized anxiety scales
Number of subjects: 0
Study 36341537 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity item response options on depression and generalized anxiety scales
Number of subjects: 0
Study 34016346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slurry (4 g⋅kg ‐1 body weight, 0.5 °C)
Number of subjects: 7
Study 34016346 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (28 °C)
Number of subjects: 7
Study 35779189 — intervention group
Group type: EXPERIMENTAL
Intervention: NX210 (0.4, 1.25, 2.5, 5, and 10 mg/kg)
Number of subjects: 39
Study 35779189 — intervention group
Group type: EXPERIMENTAL
Intervention: NX210
Number of subjects: 39
Study 35779189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 33735709 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 75 mg/day
Number of subjects: 28
Study 33735709 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/day
Number of subjects: 28
Study 33735709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 32667858 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health application + routine medical care (app group)
Number of subjects: 100
Study 32667858 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care (control group)
Number of subjects: 100
Study 35422611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (1.5 mg/kg bolus before anesthesia induction, followed by 2.0 mg/kg/h continuous infusion until end of surgery)
Number of subjects: 195
Study 35422611 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline at the same time points)
Number of subjects: 195
Study 35422611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 195
Study 35422611 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 195
Study 32863142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloride-rich intravenous fluid (0.9% saline)
Number of subjects: 1056
Study 32863142 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative SCl−
Number of subjects: 1056
Study 32863142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass duration
Number of subjects: 1056
Study 32178950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Number of subjects: 75
Study 32178950 — intervention group
Group type: COMPARATOR
Intervention: Grape seed oil (control)
Number of subjects: 75
Study 36579554 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided corticosteroid injections combined with a personalized rehabilitation program (Group A; n: 19)
Number of subjects: 37
Study 36579554 — intervention group
Group type: COMPARATOR
Intervention: US-guided corticosteroid injections alone (Group B; n: 18)
Number of subjects: 37
Study 33359269 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of 19 Gy
Number of subjects: 170
Study 33359269 — intervention group
Group type: COMPARATOR
Intervention: Two fractions of 13.5 Gy one week apart
Number of subjects: 170
Study 33407549 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH hardware provision and behavior change promotion
Number of subjects: 0
Study 35107855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (average 1.58 mg/ml DMT) in healthy volunteers
Number of subjects: 37
Study 35107855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (average 0.680 mg/ml DMT) in volunteers with SAD
Number of subjects: 37
Study 35107855 — intervention group
Group type: COMPARATOR
Intervention: Placebo in healthy volunteers
Number of subjects: 37
Study 35107855 — intervention group
Group type: COMPARATOR
Intervention: Placebo in volunteers with SAD
Number of subjects: 37
Study 33646286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulse oximetry (every 4 hours, n = 114)
Number of subjects: 229
Study 33646286 — intervention group
Group type: COMPARATOR
Intervention: Continuous pulse oximetry (n = 115)
Number of subjects: 229
Study 33646286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulse oximetry
Number of subjects: 229
Study 33646286 — intervention group
Group type: COMPARATOR
Intervention: Continuous pulse oximetry
Number of subjects: 229
Study 32455019 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ingestion of 60 mg iron and 0.4 mg folic acid
Number of subjects: 277
Study 34170518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-intensity physical exercise for 8 weeks
Number of subjects: 22
Study 34170518 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 22
Study 32779607 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne-particle abrasion (AA)
Number of subjects: 4
Study 32779607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid etching (HA)
Number of subjects: 4
Study 32779607 — intervention group
Group type: EXPERIMENTAL
Intervention: Silane coupling agent application (SL)
Number of subjects: 4
Study 32779607 — intervention group
Group type: EXPERIMENTAL
Intervention: AA/SL
Number of subjects: 4
Study 32779607 — intervention group
Group type: EXPERIMENTAL
Intervention: HA/SL
Number of subjects: 4
Study 32779607 — intervention group
Group type: EXPERIMENTAL
Intervention: AA/HA
Number of subjects: 4
Study 32779607 — intervention group
Group type: EXPERIMENTAL
Intervention: AA/HA/SL
Number of subjects: 4
Study 32779607 — intervention group
Group type: COMPARATOR
Intervention: No surface treatment (C)
Number of subjects: 4
Study 33856973 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiveness therapy
Number of subjects: 81
Study 33856973 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based schema (MBS) therapy
Number of subjects: 81
Study 33856973 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 33600915 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 440
Study 33600915 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg
Number of subjects: 440
Study 33600915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study 33727005 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable-polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 1300
Study 33727005 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer everolimus-eluting stents (DP-EES)
Number of subjects: 1300
Study 32611638 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy plus prednisone
Number of subjects: 0
Study 32611638 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 0
Study 36060196 — intervention group
Group type: EXPERIMENTAL
Intervention: 1WS (once-weekly support by specialized therapists)
Number of subjects: 675
Study 36060196 — intervention group
Group type: EXPERIMENTAL
Intervention: 1W/1BD-S (once-weekly support supplemented with one-business-day response to emails)
Number of subjects: 675
Study 36060196 — intervention group
Group type: EXPERIMENTAL
Intervention: 1WC (once-weekly support by therapists in community clinics)
Number of subjects: 675
Study 36060196 — intervention group
Group type: COMPARATOR
Intervention: 1WS
Number of subjects: 675
Study 36060196 — intervention group
Group type: COMPARATOR
Intervention: 1W/1BD-S
Number of subjects: 675
Study 36060196 — intervention group
Group type: EXPERIMENTAL
Intervention: 1WS, 1W/1BD-S, 1WC
Number of subjects: 675
Study 36060196 — intervention group
Group type: COMPARATOR
Intervention: 1WC
Number of subjects: 675
Study 33386238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue (30-min Stroop test)
Number of subjects: 25
Study 36328912 — intervention group
Group type: EXPERIMENTAL
Intervention: Active distraction (tablet)
Number of subjects: 99
Study 36328912 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 99
Study 33961295 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured supervised exercise program (Group 1, n = 15)
Number of subjects: 30
Study 33961295 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation program (Group 2, n = 15)
Number of subjects: 30
Study 32394772 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + SP app intervention (Study 1)
Number of subjects: 379
Study 32394772 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + SP app intervention (Study 2)
Number of subjects: 379
Study 32394772 — intervention group
Group type: COMPARATOR
Intervention: Control group (Study 2)
Number of subjects: 379
Study 33414526 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step phacotrabeculectomy
Number of subjects: 60
Study 33414526 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step phacotrabeculectomy
Number of subjects: 60
Study 33414526 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 60
Study 33414526 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 60
Study 32947558 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin pharmacokinetic model incorporating time‐varying creatine clearance (CrCL)
Number of subjects: 213
Study 32947558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian estimation with at least one measured serum concentration and frequent CrCL monitoring
Number of subjects: 213
Study 36217626 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture and exercise training
Number of subjects: 70
Study 36217626 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture and exercise training
Number of subjects: 70
Study 33098672 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal Problem Identification Program
Number of subjects: 2558
Study 33098672 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-associated factors
Number of subjects: 2558
Study 33098672 — intervention group
Group type: EXPERIMENTAL
Intervention: Health personnel-associated factors
Number of subjects: 2558
Study 35485835 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Social Anxiety (CBT-SA)
Number of subjects: 96
Study 35485835 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Remediation (CR)
Number of subjects: 96
Study 32835417 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate treatment
Number of subjects: 1000
Study 32739319 — intervention group
Group type: EXPERIMENTAL
Intervention: XP‐RT (adjuvant concurrent chemo‐radiotherapy)
Number of subjects: 440
Study 32739319 — intervention group
Group type: COMPARATOR
Intervention: XP (chemotherapy alone)
Number of subjects: 440
Study 35654577 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 3185
Study 32396700 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PrEP initiation
Number of subjects: 7830
Study 32396700 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP users
Number of subjects: 7830
Study 32396700 — intervention group
Group type: COMPARATOR
Intervention: PrEP initiation across randomized groups
Number of subjects: 7830
Study 35300930 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM for Teen Moms intervention
Number of subjects: 295
Study 34282831 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-assisted injections
Number of subjects: 42
Study 34282831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannula-assisted injections
Number of subjects: 42
Study 34282831 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 42
Study 35987532 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE
Number of subjects: 81
Study 35987532 — intervention group
Group type: COMPARATOR
Intervention: RP
Number of subjects: 81
Study 36368760 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour at 38+0 to 38+4 weeks' gestation
Number of subjects: 4000
Study 36368760 — intervention group
Group type: COMPARATOR
Intervention: Standard care as per each hospital trust (median gestation of delivery 39+4)
Number of subjects: 4000
Study 33769675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1065
Study 33769675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1065
Study 33769675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 1065
Study 33769675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1065
Study 33769675 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1065
Study 35228574 — intervention group
Group type: EXPERIMENTAL
Intervention: Male infants
Number of subjects: 0
Study 35228574 — intervention group
Group type: COMPARATOR
Intervention: Female infants
Number of subjects: 0
Study 32438301 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice group (liquid enriched with carbohydrate and protein)
Number of subjects: 80
Study 32438301 — intervention group
Group type: COMPARATOR
Intervention: Control group (200 mL of inert solution)
Number of subjects: 80
Study 33597589 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin D3
Number of subjects: 0
Study 33597589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35980634 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic opioid risk tool
Number of subjects: 36
Study 35980634 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative-enhanced probabilistic risk tool
Number of subjects: 36
Study 35980634 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 36
Study 34534529 — intervention group
Group type: EXPERIMENTAL
Intervention: Blalock‐Taussig shunts (mBTS)
Number of subjects: 544
Study 34534529 — intervention group
Group type: COMPARATOR
Intervention: Right ventricle‐to‐pulmonary artery (RV‐PA) shunts
Number of subjects: 544
Study 32820551 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review writing
Number of subjects: 24
Study 32820551 — intervention group
Group type: COMPARATOR
Intervention: Painting (active control)
Number of subjects: 24
Study 32820551 — intervention group
Group type: COMPARATOR
Intervention: Coffee from around the world (active control)
Number of subjects: 24
Study 35460725 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin (0.5-1.0 g/kg over 3 hours)
Number of subjects: 100
Study 35460725 — intervention group
Group type: COMPARATOR
Intervention: Plasmalyte (30 ml/kg over 3 hours)
Number of subjects: 100
Study 35460725 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% albumin
Number of subjects: 100
Study 35460725 — intervention group
Group type: COMPARATOR
Intervention: Plasmalyte
Number of subjects: 100
Study 34672159 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized - exercise training (ET) for 12 weeks
Number of subjects: 20
Study 34672159 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation without ET for 12 weeks
Number of subjects: 20
Study 33399254 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib added to adjuvant endocrine therapy
Number of subjects: 0
Study 33399254 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant endocrine therapy alone
Number of subjects: 0
Study 33481463 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth exercise intervention (functional circuit exercise training via videoconferencing, 3 times weekly for 12 weeks)
Number of subjects: 80
Study 33481463 — intervention group
Group type: COMPARATOR
Intervention: Delayed entry control group
Number of subjects: 80
Study 34138863 — intervention group
Group type: EXPERIMENTAL
Intervention: Single STH infection
Number of subjects: 393
Study 34138863 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild STH infection
Number of subjects: 393
Study 34138863 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger children
Number of subjects: 393
Study 34138863 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the examined variables
Number of subjects: 393
Study 35554515 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic ring laparoscopic Roux‐en‐Y gastric bypass (SR‐LRYGB)
Number of subjects: 114
Study 35554515 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 114
Study 33853731 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose almonds (73±5 g/d)
Number of subjects: 0
Study 33853731 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose almonds (38±3 g/d) plus half-dose muffins
Number of subjects: 0
Study 33853731 — intervention group
Group type: COMPARATOR
Intervention: Full-dose muffins (control)
Number of subjects: 0
Study 32494210 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 3 weeks)
Number of subjects: 72
Study 32494210 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 72
Study 35080256 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg plus alfosbuvir 400 mg daily (Cohort A)
Number of subjects: 124
Study 35080256 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg plus alfosbuvir 600 mg daily (Cohort B)
Number of subjects: 124
Study 35080256 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg plus alfosbuvir 800 mg daily (Cohort C)
Number of subjects: 124
Study 34871153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (CIC) 40, 80, or 160 µg/day
Number of subjects: 0
Study 34871153 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide (CIC) 160 µg/day
Number of subjects: 0
Study 34871153 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide (CIC) 80 or 160 µg/day
Number of subjects: 0
Study 34871153 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide (CIC) with placebo
Number of subjects: 0
Study 35809008 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic sacral dressing plus standard care
Number of subjects: 130
Study 35809008 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 130
Study 33484216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac CT-guided LV lead implantation
Number of subjects: 18
Study 33484216 — intervention group
Group type: EXPERIMENTAL
Intervention: LV stimulation in CT target segments
Number of subjects: 18
Study 33484216 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse remodeling at 6 months
Number of subjects: 18
Study 35714057 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop (n = 65)
Number of subjects: 131
Study 35714057 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 66)
Number of subjects: 131
Study 32010972 — intervention group
Group type: COMPARATOR
Intervention: 24-hour Foley catheter (Group A)
Number of subjects: 201
Study 32010972 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour Foley catheter (Group B)
Number of subjects: 201
Study 34844129 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation
Number of subjects: 84
Study 34844129 — intervention group
Group type: EXPERIMENTAL
Intervention: Montessori-based
Number of subjects: 84
Study 33181518 — intervention group
Group type: EXPERIMENTAL
Intervention: 'bare' group (all pubic hair removed)
Number of subjects: 42
Study 33181518 — intervention group
Group type: EXPERIMENTAL
Intervention: 'hair' group (no pubic hair removed)
Number of subjects: 42
Study 33181518 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 participants)
Number of subjects: 42
Study 34265236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 12 mg on day 1 and 2 post enrolment
Number of subjects: 0
Study 34265236 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study 34265236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 34265236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33228654 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report via telephone questionnaires
Number of subjects: 145
Study 33228654 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report via diaries
Number of subjects: 145
Study 33228654 — intervention group
Group type: COMPARATOR
Intervention: Administrative data
Number of subjects: 145
Study 35553398 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient maternal vitamin D (< 50 nmol/l) during gestational weeks 18-22
Number of subjects: 176
Study 35553398 — intervention group
Group type: COMPARATOR
Intervention: Sufficient maternal vitamin D (≥ 50 nmol/l) during gestational weeks 18-22
Number of subjects: 176
Study 32506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 32506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-E
Number of subjects: 0
Study 32506513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall change in MetS-Z
Number of subjects: 0
Study 32506513 — intervention group
Group type: EXPERIMENTAL
Intervention: Change-in-AST Z-score
Number of subjects: 0
Study 33048951 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed model based on maternal fundal height
Number of subjects: 20
Study 33048951 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed growth chart based on proposed model
Number of subjects: 20
Study 33048951 — intervention group
Group type: COMPARATOR
Intervention: Existing fetal growth charts
Number of subjects: 20
Study 36774103 — intervention group
Group type: EXPERIMENTAL
Intervention: Micellar casein (MCN)
Number of subjects: 10
Study 36774103 — intervention group
Group type: COMPARATOR
Intervention: Sodium caseinate (SCN)
Number of subjects: 10
Study 36774103 — intervention group
Group type: COMPARATOR
Intervention: Whey protein concentrate (WPC)
Number of subjects: 10
Study 34554201 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (fluorouracil dosing every 2 weeks)
Number of subjects: 0